Drug resistance in targeted cancer therapies with RAF inhibitors

Hyperactive RAS/RAF/MEK/ERK signaling has a well-defined role in cancer biology. Targeting this pathway results in complete or partial regression of most cancers. In recent years, cancer genomic studies have revealed that genetic alterations that aberrantly activate the RAS/RAF/MEK/ERK signaling mai...

Descripción completa

Detalles Bibliográficos
Autores principales: Degirmenci, Ufuk, Yap, Jiajun, Sim, Yuen Rong M., Qin, Shiru, Hu, Jiancheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094075/
https://www.ncbi.nlm.nih.gov/pubmed/35582307
http://dx.doi.org/10.20517/cdr.2021.36

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9094075/
https://www.ncbi.nlm.nih.gov/pubmed/35582307
http://dx.doi.org/10.20517/cdr.2021.36

Ejemplares similares